The outbreak of new coronavirus disease-2019 or COVID-19 infection has become a global health emergency at the beginning of this year. Currently, no specific vaccines and therapeutic medications are available to treat this disease. Even though several vaccine candidates are under investigation, it will take some time to make them available for the mass population. Hyperinflammation due to excessive cytokine release in COVID-19 infected patients with other inflammatory diseases makes lethal effects, including multiorgan failure and even death. The increasing gain of insight about the pathophysiology of this novel coronavirus enables experts to consider some commonly available anti-inflammatory drugs as potential immunomodulatory candidates for the cytokine release syndrome (CRS) treatment in COVID-19 infection. This review was conducted to discuss all the possible signalling pathways involved in COVID-19 related hyperinflammation. It also emphasized on the efficacy of both synthetic and natural therapeutic drugs for immunomodulation in the COVID-19 related CRS treatment.

Background and Aim: Xerostomia, is a chronic and common symptom of dry mouth that many patients report when the their doctor or dentist or oral hygienist. As far as Corona virus spreading widely, it is khown as one of the latest etiology complication. Salivary reduction causes serious damages to the oral and pharyngeal mucosa due to dryness, Same as ora pharyngeal mucosa discontinuity. The aim of this study was to evaluate dry mouth and its necessary treatment considera related articles in patients with Covid19, as important and know complicate. Material and Methods: by searching the keywords, COVID-19; Therapeutics; Xerostomia; Salivary glands in data base as pubmed; Google scholar; scopus; SID; net, 40 articles that published between the years 2016-2020, which are conform our inclusive and exclusive factors, were selected. Results: Secondary to taste dysfunction (59. 5%), Xerostomia (45. 9%) is the most prevalent condition related to corona i 74. 5% of corona infected who experience Xerostomia, announced that they have had the signs of Xerostomia before cov diagnosis. Some medications used in the treatment of Covid-19, such as antiviral drugs (Remdesivir and Ritonavir) and antimuscarinic drugs, also causes dry mouth. There is a wide range and different efficiencies of dry mouth treatments. Th emerged therapies have also been effective in treating dry mouth and have shown promising results. Conclusion: The corona virus can affected salivary glands function, directly and indirectly. It cause changes in amount a quality of saliva, the important and significant result of which is dry mouth. It could be secondary to the destructive activ the virus, or secondary to the use of therapeutic drugs. Due to the widespread effects of dry mouth on patients' quality of important to consider concomitant treatment of dry mouth in patients who affected by covid-19 currently or in past.